Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) insider Mark E. Dmytruk sold 29,762 shares of Ginkgo Bioworks stock in a transaction on Wednesday, March 15th. The stock was sold at an average price of $1.31, for a total value of $38,988.22. Following the transaction, the insider now directly owns 530,736 shares of the company’s stock, valued at approximately $695,264.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Ginkgo Bioworks Trading Down 3.0 %
Shares of DNA stock opened at $1.28 on Friday. The firm has a 50-day moving average price of $1.66 and a 200 day moving average price of $2.14. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $1.19 and a twelve month high of $4.91. The company has a market capitalization of $2.48 billion, a price-to-earnings ratio of -0.99 and a beta of 0.91.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on the company. Berenberg Bank assumed coverage on Ginkgo Bioworks in a research note on Monday, November 28th. They set a “buy” rating and a $6.00 price target for the company. BTIG Research cut their price target on Ginkgo Bioworks from $4.00 to $3.00 in a research note on Sunday, March 5th. Finally, Raymond James cut their target price on shares of Ginkgo Bioworks from $6.00 to $5.00 and set an “outperform” rating for the company in a research note on Friday, March 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $4.39.
Institutional Inflows and Outflows
Ginkgo Bioworks Company Profile
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.